Cure&Sure Biotech Co., LTD   Report issue

For profit Phase 2 Phase 3
Founded: China (2005)
Status: Defunct (2020)

Organization Overview

First Clinical Trial
2012
NCT02133079
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Cure&Sure Biotech Co., LTD

Active Ingredients

Drugs in Phase 3 Trials (1)

gp96 (3 trials)

Drugs in Phase 2 Trials (7)

autologous gp96 vaccination (2 trials)

gimeracil (1 trial)

oteracil (1 trial)

oxaliplatin (eloxatin) (1 trial)

s-1 (1 trial)

tegafur (1 trial)

temozolomide (temodar) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Glioblastoma (Phase 2)

Glioma (Phase 2)

Liver Neoplasms (Phase 3)

Stomach Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 8